The FDA's March 30th, 2023 announcement that they will begin issuing Refuse to Accept (RTA) letters for device submissions that do not meet their cybersecurity guidance has added pressure for med tech companies to formalize their cybersecurity strategies.
MedCrypt was founded to help healthcare technology companies build products that are secure by design. Our team consists of former medical device engineers, cybersecurity experts, and regulators. MedCrypt's software and services can help you satisfy these new regulatory requirements, and focus on bringing life-changing clinical features to your patients.
We understand how quickly the security landscape is changing, and how important it is to your business and patients to ensure the maximum probability of regulatory approval. Contact us to learn how we can help with:
The FDA is moving forward with its authority under the new section 524B of the FD&C act.
This means that it is now a requirement for medical device manufacturers to:
You need to start working on your remediation plan today to avoid any unexpected delays.
The FDA will issue its final guidance in September. As of October 1, 2023, the FDA will start sending Refuse to Accept responses to any medical device manufacturers who have not submitted the requisite strategy and documentation to show that their device is secure today and that they have a plan to maintain that security throughout the lifecycle of the device.
Contact us today so we can help navigate potential pitfalls to ensure that your FDA submission is complete.
.webp)